News

No Benefit From Short-Term Androgen Deprivation Added to Dose-Escalated Radiotherapy for Prostate Cancer

05/24/2023

Allison Casey

A phase 3 trial found the addition of short-term androgen deprivation to dose-escalated radiotherapy did not improve the overall survival among patients with intermediate-risk prostate cancer.

A phase 3 trial found the...

05/24/2023

Oncology

News

Fluorescent Tracer OTL78 Shows Potential for Prostate Cancer Detection

05/02/2023

Allison Casey

According to a first-in-patient study, the prostate-specific membrane antigen (PSMA)-targeted fluorescent tracer OTL78 was well-tolerated and showed potential in improving prostate cancer detection.

According to a first-in-patient...

05/02/2023

Oncology

News

Enzalutamide Plus Abiraterone Not Recommended for Patients With Metastatic Castration-Resistant Prostate Cancer

04/12/2023

According to phase 3 trial results, enzalutamide in combination with abiraterone acetate and prednisone did not prolong overall survival for patients with metastatic castration-resistant prostate cancer in the first-line setting.

According to phase 3 trial...

04/12/2023

Oncology

Conference Coverage

Abiraterone Plus Olaparib Prolonged rPFS, Improved OS Among Patients With Castration-Resistant Prostate Cancer

02/17/2023

Jordan Kadish

According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...

According to results presented...

02/17/2023

Oncology

Conference Coverage

Talazoparib Plus Enzalutamide Improves PFS for Metastatic Castration-Resistant Prostate Cancer

02/16/2023

Allison Casey

According to phase 3 interim data presented at the 2023 ASCO GU Symposium, talazoparib plus enzalutamide was superior to standard-of-care enzalutamide in imaging-based progression-free survival for patients with metastatic...

According to phase 3 interim...

02/16/2023

Oncology

Conference Coverage

Rucaparib Improved Survival Outcomes vs Docetaxel and Androgen Pathway Inhibitor Therapy Among Patients with Metastatic Castration-Resistant Prostate Cancer

02/16/2023

Allison Casey

According to phase 3 interim data presented at the 2023 ASCO GU Symposium, rucaparib improved radiographic progression-free survival vs either docetaxel or abiraterone/enzalutamide for patients with metastatic castration-resistant prostate...

According to phase 3 interim...

02/16/2023

Oncology

Conference Coverage

Darolutamide Plus ADT and Docetaxel As a New Standard of Care for Hormone-Sensitive Prostate Cancer

02/16/2023

Allison Casey

According to phase 3 trial data presented at the 2023 ASCO GU Symposium, darolutamide plus androgen-deprivation therapy and docetaxel improved the overall survival of patients with metastatic hormone-sensitive prostate cancer regardless of...

According to phase 3 trial data...

02/16/2023

Oncology

Conference Coverage

BXCL701/Talabostat As a Treatment Option for Refractory Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype

02/16/2023

Allison Casey

According to phase 2a trial results presented at the 2023 ASCO GU Symposium, the oral small molecule inhibitor of dipeptidyl peptidases, BXCL701, showed promise among patients with refractory metastatic castration-resistant prostate cancer of...

According to phase 2a trial...

02/16/2023

Oncology

News

MRI Guidance for Stereotactic Body Radiotherapy Reduced Toxic Effects Among Patients With Prostate Cancer

02/10/2023

MRI-guided stereotactic body radiotherapy reduced the incidence of acute genitourinary and gastrointestinal toxic effects among patients with prostate cancer, compared to CT-guided therapy.

MRI-guided stereotactic body...

02/10/2023

Oncology

News

ADT Sequencing With Radiotherapy for Nonmetastatic Prostate Cancer

11/04/2022

Allison Casey

Findings from a pooled analysis reveal ADT sequencing significantly impacts clinical outcomes in patients with prostate cancer and concurrent/adjuvant ADT should be the standard of care in combination with prostate-only radiotherapy.

Findings from a pooled analysis...

11/04/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology